July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Risk factors for hydroxychloroquine retinopathy in the Korean population.
Author Affiliations & Notes
  • KIM SEEUN
    Cheil eye hospital, Daegu , Korea (the Republic of)
    Catholic University of Daegu School of Medicine, Daegu, Korea (the Republic of)
  • JUNG HEUM HONG
    Catholic University of Daegu School of Medicine, Daegu, Korea (the Republic of)
  • SI DONG KIM
    Catholic University of Daegu School of Medicine, Daegu, Korea (the Republic of)
  • YOON YOUNG KIM
    Catholic University of Daegu School of Medicine, Daegu, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   KIM SEEUN, None; JUNG HEUM HONG, None; SI DONG KIM, None; YOON YOUNG KIM, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1837. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      KIM SEEUN, JUNG HEUM HONG, SI DONG KIM, YOON YOUNG KIM; Risk factors for hydroxychloroquine retinopathy in the Korean population.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1837.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Several studies have reported risk factors for hydroxychloroquine (HCQ) retinopathy, but data are limited for patients of Asian ancestry. The aim of this study was to investigate the rate of and factors for HCQ retinopathy in the Korean population.

Methods : There were 123 patients enrolled in this study who were using or had used HCQ. Retinopathy was detected using spectral domain optical coherence tomography, fundus autofluorescence, multifocal electroretinography, and automated visual field testing. Binary logistic regression analysis was performed to identify factors associated with HCQ retinopathy.

Results : Mean duration of HCQ use and mean HCQ dose in study participants was 10.1 years and 6.4 mg/kg, respectively. We found 17 patients (13.8%) with HCQ retinopathy among 123 patients. Patients with retinopathy took HCQ ranging from 6.7–21.9 years and daily dosage ranging from 4.9–9.1 mg/kg. Only 1 patient had retinal toxicity among patients with daily dose < 5.0 mg/kg. These factors increased the risk of HCQ retinopathy: longer duration of HCQ use [adjusted OR (aOR) = 4.71, 95% CI 2.18–10.15 for duration of HCQ use in 5-yr increments], higher daily HCQ dose (aOR = 3.34, 95% CI 1.03–10.80 for daily HCQ dose in 100-mg increments), and the presence of kidney disease (aOR = 8.56, 95% CI 1.15–64.00).

Conclusions : HCQ retinopathy is associated with duration of HCQ use, daily HCQ dose, and presence of kidney disease. Proper dosing of maximum 5 mg/kg and regular screening according to risk factors are important in HCQ use.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×